Without discussion of (1)actual revenue beginning to flow in, and, (2) the start of vaccine clinical trials in the good old US of A, they’re not getting more than 5.00 a share. That’s why they aren’t ready for the IPO. JMHO.
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
